Phase II data with Bavarian Nordic's newly-licensed immunotherapy due H1 2012
This article was originally published in Scrip
Executive Summary
Danish company Bavarian Nordic said it expects to report Phase II study data for its immunotherapy candidate, CV-301, from an ongoing study in metastatic breast cancer in the first half of next year. Bavarian Nordic obtained the rights to CV-301, an off-the-shelf product candidate for multiple cancers, in October this year through an expanded collaboration with the US National Cancer Institute and licence with the US National Institutes of Health.